Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

CareDx Inc

Healthcare US CDNA

25.26USD
0.21(0.84%)

Last update at 2026-06-23T18:29:00Z

Day Range

24.5025.64
LowHigh

52 Week Range

10.9623.24
LowHigh

Fundamentals

  • Previous Close 25.05
  • Market Cap1066.20M
  • Volume240772
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-7.79500M
  • Revenue TTM379.80M
  • Revenue Per Share TTM7.13
  • Gross Profit TTM 256.57M
  • Diluted EPS TTM-0.4

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -21.08300M 52.86M -190.14300M -76.23400M -32.08800M
Minority interest - - - - -
Net income -21.35400M 52.55M -190.28400M -76.61300M -30.66200M
Selling general administrative 107.56M 123.78M 117.87M 100.40M 74.96M
Selling and marketing expenses 102.64M 81.72M 83.33M 96.03M 77.25M
Gross profit 254.43M 224.16M 178.32M 209.58M 199.01M
Reconciled depreciation 20.42M 19.76M 19.82M 16.01M 11.88M
Ebit -21.08300M -53.75200M -104.74300M -77.23100M -29.72600M
Ebitda -0.66700M -33.99500M -84.91900M -77.33800M -29.83200M
Depreciation and amortization 20.42M 19.76M 19.82M -0.10700M -0.10600M
Non operating income net other - - - - -2.52200M
Operating income -21.01600M 40.77M -203.36300M -77.23100M -29.72600M
Other operating expenses 400.82M 293.02M 483.69M 399.02M 326.12M
Interest expense - - - 3.76M 9.63M
Tax provision 0.27M 0.31M 0.14M 0.38M -1.42600M
Interest income 9.17M 11.77M 11.87M 3.76M 0.16M
Net interest income 9.17M 11.77M 11.87M 3.76M 0.16M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.27M 0.31M 0.14M 0.38M -1.42600M
Total revenue 379.81M 333.79M 280.32M 321.79M 296.40M
Total operating expenses 275.44M 183.39M 381.69M 286.81M 228.73M
Cost of revenue 125.38M 109.63M 102.00M 112.21M 97.39M
Total other income expense net -0.06700M 12.09M 13.22M 1.00M -2.36200M
Discontinued operations - - - - -
Net income from continuing ops -21.35400M 52.55M -190.28400M -76.61300M -30.66200M
Net income applicable to common shares - - - -76.61300M -30.66200M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 413.23M 491.05M 484.62M 542.99M 566.62M
Intangible assets 31.96M 38.18M 45.70M 43.05M 50.20M
Earning assets - - - - -
Other current assets 10.59M 7.07M 7.76M 9.22M 7.93M
Total liab 110.13M 112.62M 223.29M 112.08M 100.75M
Total stockholder equity 303.10M 378.43M 261.33M 430.91M 465.88M
Deferred long term liab - - - - 0.41M
Other current liab 79.86M 70.73M 54.51M 55.10M 4.73M
Common stock 0.05M 0.05M 0.05M 0.05M 0.05M
Capital stock 0.05M 0.05M 0.05M 0.05M 0.05M
Retained earnings -735.35900M -626.24200M -678.26900M -460.44400M -383.18900M
Other liab - - - 2.70M 6.05M
Good will 40.34M 40.34M 40.34M 37.52M 36.98M
Other assets - - - 4.35M 6.05M
Cash 65.43M 114.69M 82.20M 89.92M 348.49M
Cash and equivalents - - - - -
Total current liabilities 89.85M 89.37M 78.07M 75.97M 77.30M
Current deferred revenue - 4.85M 4.75M 5.34M 55.28M
Net debt -45.75000M -86.32300M -47.97600M -50.92400M -331.09100M
Short term debt - 6.10M 5.94M 5.59M 3.96M
Short long term debt - - - - -
Short long term debt total 19.68M 28.37M 34.22M 39.00M 17.39M
Other stockholder equity 1043.92M 1013.19M 946.51M 898.81M 853.68M
Property plant equipment - - - 70.22M 40.04M
Total current assets 257.13M 351.83M 313.71M 387.85M 433.36M
Long term investments 24.16M 0.00000M - - -
Net tangible assets - - - 350.34M 378.70M
Short term investments 111.78M 145.96M 153.22M 203.17M 0.00000M
Net receivables 42.63M 64.61M 51.06M 66.31M 59.76M
Long term debt - - - - -
Inventory 26.70M 19.50M 19.47M 19.23M 17.19M
Accounts payable 9.99M 7.69M 12.87M 9.94M 13.34M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -5.51500M -8.56900M -6.96300M -7.50300M -4.67000M
Additional paid in capital - - - - -
Common stock total equity - - - - 0.05M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -383.18900M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 28.07M 2.81M 1.35M 4.35M 6.05M
Deferred long term asset charges - - - - -
Non current assets total 156.10M 139.22M 170.90M 155.14M 133.26M
Capital lease obligations 26.19M 28.37M 34.22M 39.00M 21.35M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 8.75M -0.48300M 40.45M -228.50200M 83.41M
Change to liabilities - - - -2.26900M 20.00M
Total cashflows from investing activities 2.16M -0.48300M 40.45M -228.50200M 47.71M
Net borrowings - - 0.00000M - -0.06600M
Total cash from financing activities -93.39400M -5.60600M -29.60600M -4.53500M 185.64M
Change to operating activities - - - -2.42900M 10.46M
Net income -21.35400M 52.55M -190.28400M -76.61300M -30.66200M
Change in cash -49.29400M 32.49M -7.66000M -258.25300M 213.76M
Begin period cash flow 115.27M 82.78M 90.44M 348.70M 134.94M
End period cash flow 65.98M 115.27M 82.78M 90.44M 348.70M
Total cash from operating activities 42.03M 38.05M -18.38800M -25.23900M -19.29400M
Issuance of capital stock - - 0.00000M 0.00000M 188.85M
Depreciation 20.42M 19.76M 19.82M 16.01M 11.88M
Other cashflows from investing activities -6.58800M -7.11800M 1.50M - -35.69300M
Dividends paid - - - - -2.13900M
Change to inventory -4.95900M -1.01800M 0.05M -2.85900M -6.92700M
Change to account receivables 22.52M -13.74100M 16.02M -6.66000M -24.41600M
Sale purchase of stock -87.76800M -0.52200M -27.54100M -0.64200M 2.14M
Other cashflows from financing activities -13.62100M -5.08400M -2.06500M -6.32800M -3.14700M
Change to netincome - - - 49.58M 37.95M
Capital expenditures 5.91M 6.48M 9.24M 24.33M 20.26M
Change receivables - - - - -24.41600M
Cash flows other operating - - - - -25.15500M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - 214.06M
Change in working capital 3.81M -102.30700M 106.03M -14.21700M -40.97000M
Stock based compensation 34.86M 66.41M 49.09M 46.55M 36.08M
Other non cash items 4.28M 1.83M -3.60900M 3.25M 0.30M
Free cash flow 36.12M 31.56M -27.62800M -49.57300M -39.55300M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CDNA
CareDx Inc		 0.21 0.84% 25.26 - 97.09 2.81 3.60 2.48 65.47
TMO
Thermo Fisher Scientific Inc		 5.34 1.15% 469.35 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 0.78 0.44% 178.97 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 0.18 0.14% 126.67 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 -5.19 0.95% 540.54 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.

CareDx Inc

8000 Marina Boulevard, Brisbane, CA, United States, 94005

Key Executives

Name Title Year Born
Dr. Reginald Seeto Pres, CEO & Director 1972
Dr. Peter Maag Ph.D. Exec. Director 1967
Ms. Sasha King M.B.A. Exec. Officer 1986
Mr. Marcel Konrad Sr. VP of Fin. & Accounting 1976
Mr. Alexander L. Johnson Pres of Patient and Testing Services 1974
Mr. Abhishek Jain CFO, VP, Corp. Controller, Principal Financial Officer & Principal Accounting Officer 1976
Ms. Marica Grskovic Ph.D. Chief Operating Officer NA
Mr. Abraham Ronai Esq. Gen. Counsel, Chief Admin. & Legal Officer and Sec. 1973
Mr. Ian Cooney VP of Investor Relations NA
Dr. Mickey Y. Kim M.D. Sr. VP of Corp. Devel. & Head of Global Product NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.